RT Journal Article
SR Electronic
T1 Metabolomic biomarkers from patients with Barth syndrome treated with elamipretide: insights from the TAZPOWER study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.20.20235580
DO 10.1101/2020.11.20.20235580
A1 Peter J. Oates
A1 David A. Brown
A1 Hilary J. Vernon
A1 Jon A. Gangoiti
A1 Bruce A. Barshop
YR 2020
UL http://medrxiv.org/content/early/2020/11/27/2020.11.20.20235580.abstract
AB Background Barth syndrome is an inherited disorder that results from pathogenic mutations in TAZ, the gene responsible for encoding tafazzin, an enzyme that remodels the mitochondrial phospholipid cardiolipin. Barth syndrome is characterized by heart and skeletal muscle myopathy, growth delay, and neutropenia among other features. The TAZPOWER clinical trial investigated the effects of the mitochondria-targeting peptide elamipretide in patients with Barth syndrome.Methods and findings TAZPOWER included a randomized, double-blind, crossover study of 12 weeks treatment with elamipretide or placebo in 12 patients with Barth syndrome. A broad spectrum of plasma and urine metabolites were measured using liquid chromatography-tandem mass spectrometry at baseline and after 12 weeks treatment with elamipretide or placebo. Of 51 “energy-linked” metabolites analyzed, we highlight here the effects of elamipretide on the plasma and urinary concentrations of several metabolites previously observed to be abnormal in patients with Barth syndrome. Elamipretide treatment was associated with significantly lowered medium- and short-chain acylcarnitines in plasma and urine, respectively (p < 0.05). Acetylcarnitine, 3-hydroxybutyrate, and 3-methylglutaconate trended to decrease after 12 weeks of elamipretide, but these trends did not reach statistical significance. After 12 weeks of treatment, elamipretide had no discernible effect on four amino acids previously characterized as having abnormal concentrations in patients with Barth syndrome. Lastly, elamipretide caused a significant rise in plasma taurine concentrations, an amino acid which has been observed to be decreased in patients with Barth syndrome.Conclusions As evidenced by reduced plasma and urinary content of acylcarnitines and trends for lowered ketone body 3-hydroxybutyrate, fat metabolism in Barth syndrome appears to be modified after 12 weeks of elamipretide treatment. Overall, these data are consistent with the improved mitochondrial function that may precede functional benefits with a longer duration of therapy with elamipretide in patients with Barth syndrome.Trial registration ClinicalTrials.gov NCT03098797.Summary pointsExploratory targeted metabolomic analyses of plasma and urine were performed after a double-blind, crossover trial in patients with Barth syndrome receiving elamipretide or placebo for 12 weeks.Among 51 “energy-linked” metabolites analyzed in both plasma and urine, prominent changes were observed in metabolites associated with fat metabolism.Collectively, plasma medium-chain (C6-C12) acylcarnitines were reduced after 12 weeks of elamipretide treatment in patients with Barth syndrome.Urinary acylcarnitine concentrations were also lowered with elamipretide in Barth syndrome patients, most prominently for shorter chain acylcarnitines.Elamipretide for 12 weeks also trended to lower 3-methylglutaconate and the ketone body 3-hydroxybutyrate, although these decreases did not reach statistical significance.Elamipretide also caused a significant rise in plasma taurine, which has been previously reported to be low in Barth syndrome patients.These metabolite changes may be consistent with improved mitochondrial function that precedes the functional benefits observed in patients with Barth syndrome after longer-term therapy.Competing Interest StatementP.J.O., H.J.V., J.A.G., and B.A.B. have served as consultants for Stealth BioTherapeutics Inc. D.A.B. is employed by Stealth BioTherapeutics Inc and receives compensation and equity/shares commensurate with this employment. P.J.O. owns stock and has received share options commensurate with his consulting activities with Stealth BioTherapeutics Inc.Clinical TrialNCT03098797Funding StatementThis work was funded by Stealth BioTherapeutics Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol for the TAZPOWER study was approved by the local institutional review board committee [Johns Hopkins University IRB protocol IRB00124162: "A Phase 2 Randomized, Double-Blind, Placebo-Controlled Crossover Trial to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects with Genetically Confirmed Barth Syndrome"]. The study conformed with the principles of the Declaration of Helsinki and was prospectively registered with clinicaltrials.gov (NCT03098797).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe present report highlights results from an exploratory analysis of plasma and urinary metabolic data obtained in the double-blind, crossover part of the TAZPOWER study.